Obiettivo Multiplicom will draft a business plan that is composed of the following parts:(i) selection of miRNAs for which there is substantial scientific evidence that such may be important for the diagnosis, treatment and/or prognosis of triple-negative breast cancer (“TNBC”) patients;(ii) perform a thorough analysis of the intellectual property on the selected miRNAs;(iii) start in-licensing negotiations with licensors regarding relevant intellectual property(iv) select a suitable quantitative multiplex miRNA analysis;(v) plan a European-wide, multi-center, clinical validation of the selected miRNAs using the selected multiplex quantification method (“Validation Study”); and(vi) perform a marketing study regarding the use of miRNA diagnosis/prognosis in TNBC patients;(vii) develop a competitive strategyFor part (i) Multiplicom has the support of top-notch clinical scientists (“KOLs”) in the field of miRNA in TNBC. Multiplicom will rely on its internal expertise, and expertise of its consultants to perform (ii) to (vi). This is supported by its track record of developing and commercializing novel highly multiplexed diagnostics (ISO 13485 & CE/IVD). The global 170,000 cases of TNBC (new cases in 2012) constitute the target patient population to be monitored by the validated multiplex miRNA test kit (“Kit”) such that they can be offered the best treatment of what is a multi-billion Euro pharmaceutical opportunity. From presently available data Multiplicom estimates the annual peak sales of the Kit in excess of €5M, with a gross margin of >80%, allowing further expansion of the company including new hires in all departments. Campo scientifico medical and health sciencesclinical medicineoncologybreast cancermedical and health scienceshealth sciencespersonalized medicinenatural sciencesbiological sciencesgeneticsRNAengineering and technologymedical engineeringmedical laboratory technologylaboratory samples analysis Programma(i) H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being Main Programme H2020-EU.3.1.3. - Treating and managing disease Argomento(i) PHC-12-2014-1 - Clinical research for the validation of biomarkers and/or diagnostic medical devices Invito a presentare proposte H2020-SMEInst-2014-2015 Vedi altri progetti per questo bando Bando secondario H2020-SMEINST-1-2014 Meccanismo di finanziamento SME-1 - SME instrument phase 1 Coordinatore MULTIPLICOM NV Contribution nette de l'UE € 50 000,00 Indirizzo GALILEILAAN 18 2845 NIEL Belgio Mostra sulla mappa PMI L’organizzazione si è definita una PMI (piccola e media impresa) al momento della firma dell’accordo di sovvenzione. Sì Regione Vlaams Gewest Prov. Antwerpen Arr. Antwerpen Tipo di attività Private for-profit entities (excluding Higher or Secondary Education Establishments) Collegamenti Contatta l’organizzazione Opens in new window Sito web Opens in new window Partecipazione a programmi di R&I dell'UE Opens in new window Rete di collaborazione HORIZON Opens in new window Costo totale € 71 429,00
